The ATP1B1 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human A-549 lung adenocarcinoma cell line with targeted disruption of the ATP1B1 gene. This loss-of-function model enables the study of ATP1B1-dependent processes without the constraints of gene silencing or pharmacological inhibition, providing a powerful tool for investigating the role of the Na+/K+-ATPase ??1 subunit in cellular physiology and disease.
A-549 cells are alveolar type II-like epithelial cells originally isolated from a human male lung adenocarcinoma. They are widely employed as a model system for lung adenocarcinoma biology, including studies of epithelial-mesenchymal transition, metastasis, and drug response. The epithelial morphology and adherent growth characteristics of A-549 cells make them suitable for a range of cell-based assays, and their genetic background reflects common mutations in the KRAS and STK11 genes, which are relevant to non-small cell lung cancer.
ATP1B1 encodes the ??1 subunit of the Na+/K+-ATPase, a transmembrane protein that assembles with ?? subunits (ATP1A1?C4) to form a functional ion pump. This complex maintains electrochemical gradients across the plasma membrane and also serves as a signal transducer. The ?? subunit interacts with caveolin-1 and ankyrin for membrane localization and cell adhesion, while the pump can activate Src kinase to trigger the Ras/RAF/MEK/ERK1/2 (MAPK) cascade. ATP1B1 expression is regulated by thyroid hormone, glucocorticoids, mineralocorticoids, and HIF1A. Knockout of ATP1B1 disrupts these interactions and signaling networks, altering ion homeostasis, cell adhesion, and intracellular pathway activation.
In the context of A-549 cells, ATP1B1 knockout is particularly significant for studying lung adenocarcinoma progression. Disruption of Na+/K+-ATPase function impairs ion gradients and reduces cell adhesion, which can promote a more migratory and invasive phenotype through Src/MAPK pathway activation. This model allows researchers to dissect the role of ATP1B1 in metastasis and to evaluate the effects of cardiac glycosides such as ouabain, which bind to the Na+/K+-ATPase and modulate signaling independently of ion transport. Furthermore, it provides a platform for investigating the interplay between cell adhesion and oncogenic signaling in a cancer-relevant background.
Representative applications include western blotting and RT-qPCR for validation of ATP1B1 disruption, immunofluorescence staining and flow cytometry to assess cell surface expression of pump subunits, co-immunoprecipitation to probe protein interactions, ATPase activity assays to quantify functional loss, cell adhesion and transwell migration/invasion assays to measure phenotypic changes, and drug screening for cardiac glycosides or Src/MEK inhibitors. This polyclonal knockout population is suitable for both short-term functional studies and generation of clonal derivatives. For technical inquiries or ordering information, please contact Ascent Research.
